Company: ENTXW
Filing Date: 2025-05-30
Form Type: S-3
Source: 0001178913-25-002025
Chunk: 35

Company: Entera Bio Ltd.
Filing Date: 2025-05-30
Form: S-3
Chunk 35
---
 exercise of options outstanding as of March 31, 2025, at a weighted average exercise price of $2.38 per ordinary share; |

| • | 186,936 of our ordinary shares issuable upon the exercise of restricted share units outstanding as of March 31, 2025; |

| • | 1,254,490 of our ordinary shares issuable upon the exercise of pre-funded warrants outstanding as of March 31, 2025; |

| • | 8,344,495 of our ordinary shares issuable upon the exercise of warrants outstanding as of March 31, 2025, at a weighted average exercise price of $1.00 per ordinary share; and |

| • | 3,826,277 of our ordinary shares reserved for future issuance under our 2018 Equity Incentive Plan as of March 31, 2025. |

S-3 RISK FACTORS You should carefully consider the risks and uncertainties described under “Item 1A. Risk Factors” in our 2024 Annual Report and in any updates to those risk factors in our Quarterly Reports on Form 10-Q or subsequent Annual Reports on Form 10-Ks and Quarterly Reports on Form 10-Q incorporated by reference herein, as well as the other information in this prospectus before making an investment in our ordinary shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our ordinary shares could decline and you could lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors. Risks related to this offering and ownership of our ordinary shares The price of our ordinary shares may be volatile, and holders of our ordinary shares could lose all or part of their investment. The price of securities for publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of our ordinary shares on Nasdaq may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited to:

| • | clinical trial results and the timing of the release of such results; |

| • | the amount of our cash resources and our ability to obtain